[{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2025-02-25T13:55:14.969Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-20"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"c62a7f73-b1c2-406a-b3bd-f74ccdc4bd18","acronym":"KOMET-007","url":"https://clinicaltrials.gov/study/NCT05735184","created_at":"2023-02-21T16:01:44.880Z","updated_at":"2024-07-02T16:35:03.357Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML","source_id_and_acronym":"NCT05735184 - KOMET-007","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • daunorubicin • Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-16"},{"id":"6c05718b-8a7f-4a20-bf78-b51f8a8735e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052813","created_at":"2023-09-25T14:10:32.555Z","updated_at":"2024-07-02T16:35:18.364Z","phase":"Phase 1/2","brief_title":"A Study of BN104 in the Treatment of Acute Leukemia","source_id_and_acronym":"NCT06052813","lead_sponsor":"BioNova Pharmaceuticals (Shanghai) LTD.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/16/2023","start_date":" 09/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-21"},{"id":"319e00c1-4042-4b5b-bae6-7484ffcf0d6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02880293","created_at":"2021-01-18T14:08:25.525Z","updated_at":"2024-07-02T16:35:28.538Z","phase":"","brief_title":"Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","source_id_and_acronym":"NCT02880293","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 11/20/2023","primary_completion_date":" 11/20/2023","study_txt":" Completion: 11/20/2023","study_completion_date":" 11/20/2023","last_update_posted":"2023-11-21"}]